Jazz Pharmaceuticals (JAZZ) Debt to Equity (2016 - 2025)
Jazz Pharmaceuticals (JAZZ) has 16 years of Debt to Equity data on record, last reported at $1.35 in Q3 2025.
- For Q3 2025, Debt to Equity fell 7.11% year-over-year to $1.35; the TTM value through Sep 2025 reached $1.35, down 7.11%, while the annual FY2024 figure was $1.49, 2.39% down from the prior year.
- Debt to Equity reached $1.35 in Q3 2025 per JAZZ's latest filing, down from $1.45 in the prior quarter.
- Across five years, Debt to Equity topped out at $2.09 in Q3 2022 and bottomed at $0.49 in Q1 2021.
- Average Debt to Equity over 5 years is $1.54, with a median of $1.54 recorded in 2024.
- Peak YoY movement for Debt to Equity: skyrocketed 242.13% in 2022, then decreased 21.49% in 2023.
- A 5-year view of Debt to Equity shows it stood at $1.53 in 2021, then increased by 21.58% to $1.86 in 2022, then decreased by 17.59% to $1.53 in 2023, then fell by 2.39% to $1.49 in 2024, then decreased by 9.25% to $1.35 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were $1.35 in Q3 2025, $1.45 in Q2 2025, and $1.28 in Q1 2025.